As of 2026-03-16, the Relative Valuation of Neurocrine Biosciences Inc (NBIX) is 91.89 USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.78 USD, the upside of Neurocrine Biosciences Inc based on Relative Valuation is -29.2%.
The range of the Relative Valuation is 43.01 - 131.46 USD.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 19.3x | 11.6x |
| Forward P/E multiples | 19.9x - 24.4x | 23.8x |
| Fair Price | 43.01 - 131.46 | 91.89 |
| Upside | -66.9% - 1.3% | -29.2% |
| Date | P/E |
| 2026-03-13 | 27.04 |
| 2026-03-12 | 26.62 |
| 2026-03-11 | 26.99 |
| 2026-03-10 | 27.05 |
| 2026-03-09 | 27.07 |
| 2026-03-06 | 26.69 |
| 2026-03-05 | 27.01 |
| 2026-03-04 | 27.80 |
| 2026-03-03 | 27.32 |
| 2026-03-02 | 27.58 |
| 2026-02-27 | 27.55 |
| 2026-02-26 | 27.22 |
| 2026-02-25 | 27.32 |
| 2026-02-24 | 27.28 |
| 2026-02-23 | 26.75 |
| 2026-02-20 | 26.80 |
| 2026-02-19 | 27.10 |
| 2026-02-18 | 26.75 |
| 2026-02-17 | 26.62 |
| 2026-02-13 | 25.86 |
| 2026-02-12 | 25.65 |
| 2026-02-11 | 28.63 |
| 2026-02-10 | 28.68 |
| 2026-02-09 | 29.08 |
| 2026-02-06 | 29.42 |
| 2026-02-05 | 28.74 |
| 2026-02-04 | 28.72 |
| 2026-02-03 | 28.95 |
| 2026-02-02 | 28.67 |
| 2026-01-30 | 28.35 |
| 2026-01-29 | 28.74 |
| 2026-01-28 | 28.05 |
| 2026-01-27 | 27.89 |
| 2026-01-26 | 28.02 |
| 2026-01-23 | 28.37 |
| 2026-01-22 | 28.62 |
| 2026-01-21 | 28.21 |
| 2026-01-20 | 28.03 |
| 2026-01-16 | 27.58 |
| 2026-01-15 | 27.78 |
| 2026-01-14 | 28.19 |
| 2026-01-13 | 27.55 |
| 2026-01-12 | 27.64 |
| 2026-01-09 | 28.29 |
| 2026-01-08 | 28.24 |
| 2026-01-07 | 29.30 |
| 2026-01-06 | 28.62 |
| 2026-01-05 | 28.33 |
| 2026-01-02 | 29.29 |
| 2025-12-31 | 29.55 |